Triluminate Pivotal Trial is a randomized trial in which patients with severe tricuspid regurgitation at intermediate or greater risk for mortality with tricuspid valve surgery are randomized in 1:1 fashion to TriClip device treatment (Abbott Structural, Santa Clara, CA) or Medical Therapy. 700 participants will be enrolled in the study. Estimated primary completion date is August 2022. The primary outcome is a hierarchical composite of number of participants with Tricuspid valve surgery, rate of heart failure hospitalizations and assessment of quality of life at 12 months.

All Editors: Kalkidan Bishu, MD, MS, FSCAI. 

All Structural Clinical Practice

Including recently published studies, coverage of late-breaking science, updates from clinical trials and registries, and complex case presentations. 

Clinical Interest Article

PARTNER 3—Coverage of TCT 2021

Two-year economic outcomes from a randomized trial of TAVR vs. SAVR in patients at low surgical risk.
Clinical Interest Article

TRISCEND—Coverage of TCT 2021

Six-month outcomes of transfemoral tricuspid valve replacement in patients with tricuspid regurgitation